Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 12 de 12
1.
Am J Trop Med Hyg ; 90(6): 1117-1123, 2014 Jun.
Article En | MEDLINE | ID: mdl-24615139

Patients with acute uncomplicated Plasmodium falciparum malaria have no evident neurologic disorder, vital organ dysfunction, or other severe manifestations of infection. Nonetheless, parasitized erythrocytes cytoadhere to the endothelium throughout their microvasculature, especially within the brain. We aimed to determine if 3 Tesla magnetic resonance imaging studies could detect evidence of cerebral abnormalities in these patients. Within 24 hours of admission, initial magnetic resonance imaging examinations found a lesion with restricted water diffusion in the mid-portion of the splenium of the corpus callosum of 4 (40%) of 10 male patients. The four patients who had a splenial lesion initially had evidence of more severe hemolysis and thrombocytopenia than the six patients who had no apparent abnormality. Repeat studies four weeks later found no residua of the lesions and resolution of the hematologic differences. These observations provide evidence for acute cerebral injury in the absence of severe or cerebral malaria.


Antimalarials/administration & dosage , Corpus Callosum/pathology , Malaria, Falciparum/pathology , Acute Disease , Adult , Artemisinins/administration & dosage , Chloroquine/administration & dosage , Corpus Callosum/parasitology , Drug Therapy, Combination , Follow-Up Studies , Hemolysis , Humans , Magnetic Resonance Imaging , Malaria, Falciparum/diagnostic imaging , Malaria, Falciparum/drug therapy , Male , Middle Aged , Parasitemia , Primaquine/administration & dosage , Prospective Studies , Radiography , Thailand , Thrombocytopenia , Young Adult
2.
Ophthalmic Plast Reconstr Surg ; 29(6): 424-7, 2013.
Article En | MEDLINE | ID: mdl-24220098

PURPOSE: Outcome evaluation in ocular adnexal lymphoma (OAL) is based on clinical assessment and conventional volumetric changes in tumor size. The purpose of this retrospective study was to compare if changes in apparent diffusion coefficient (ADC) tumor values obtained by diffusion-weighted MRI corresponded to changes in enhancing tumor volume in the evaluation of early treatment response or failure in patients with OAL. METHODS: A retrospective case series analysis of conventional contrast-enhanced orbital MRI and diffusion-weighted sequences was performed on 8 pathologically confirmed OAL tumors before and after therapy. Mean ADC values and normalized ADC ratios were obtained using a region-of-interest analysis method on enhancing OAL lesions; tumor volumes were calculated using a manual segmentation method. Changes in tumor volume, mean ADC tumor values, and normalized ADC ratios were compared before and after therapy using a Wilcoxon rank-sum test. RESULTS: Overall, a significant difference was found in mean ADC values and normalized ADC ratios within OAL tumors before and after therapy (p < 0.05), irrespective of the type of therapy administered. There was a trend toward decreased mean enhancing tumor volume after therapy (p = 0.161). An increase in ADC values and a decrease in enhancing tumor volume after therapy correlated with a positive treatment response in 7 of 8 tumors; a decrease in ADC values and an increase in enhancing tumor volume after therapy correlated with a negative treatment response in 1 of 8 tumors. CONCLUSIONS: Tracking changes in tumor ADC values after various treatment regimens for OAL may be useful in predicting early treatment response or failure and can provide complementary information that corresponds to conventional volume changes in tumor size. Further validation of these preliminary results in larger prospective randomized trials is needed.


Diffusion Magnetic Resonance Imaging/methods , Lymphoma/diagnosis , Orbital Neoplasms/diagnosis , Antineoplastic Agents/therapeutic use , Contrast Media , Humans , Lymphoma/therapy , Orbital Neoplasms/therapy , Pilot Projects , Radioimmunotherapy/methods , Regression Analysis , Retrospective Studies
3.
J Am Coll Radiol ; 8(8): 532-8, 2011 Aug.
Article En | MEDLINE | ID: mdl-21807345

Stroke is the sudden onset of focal neurologic symptoms due to ischemia or hemorrhage in the brain. Current FDA-approved clinical treatment of acute ischemic stroke involves the use of the intravenous thrombolytic agent recombinant tissue plasminogen activator given <3 hours after symptom onset, following the exclusion of intracerebral hemorrhage by a noncontrast CT scan. Advanced MRI, CT, and other techniques may confirm the stroke diagnosis and subtype, demonstrate lesion location, identify vascular occlusion, and guide other management decisions but, within the first 3 hours after ictus, should not delay or be used to withhold recombinant tissue plasminogen activator therapy after the exclusion of acute hemorrhage on noncontrast CT scans. MR diffusion-weighted imaging is highly sensitive and specific for acute cerebral ischemia and, when combined with perfusion-weighted imaging, may be used to identify potentially salvageable ischemic tissue, especially in the period >3 hours after symptom onset. Advanced CT perfusion methods improve sensitivity to acute ischemia and are increasingly used with CT angiography to evaluate acute stroke as a supplement to noncontrast CT. The ACR Appropriateness Criteria(®) are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.


Cerebrovascular Disorders/diagnosis , Practice Guidelines as Topic , Humans , Magnetic Resonance Imaging , Radiation Dosage , Radiology , Societies, Medical , Tomography, X-Ray Computed , United States
4.
Neurosurgery ; 69(6): 1272-9; discussion 1279-80, 2011 Dec.
Article En | MEDLINE | ID: mdl-21562434

BACKGROUND: Convection-enhanced delivery of chemotherapeutics for the treatment of malignant glioma is a technique that delivers drugs directly into a tumor and the surrounding interstitium through continuous, low-grade positive-pressure infusion. This allows high local concentrations of drug while overcoming the limitations imposed by toxicity and the blood-brain barrier in systemic therapies that prevent the use of many potentially effective drugs. OBJECTIVE: To examine the safety profile of a conventional chemotherapeutic agent, topotecan, via convection-enhanced delivery in the treatment of recurrent malignant gliomas and secondarily to assess radiographic response and survival. METHODS: We performed a prospective, dose-escalation phase Ib study of the topoisomerase-I inhibitor topotecan given by convection-enhanced delivery in patients with recurrent malignant gliomas. RESULTS: Significant antitumor activity as described by radiographic changes and prolonged overall survival with minimal drug-associated toxicity was demonstrated. A maximum tolerated dose was established for future phase II studies. CONCLUSION: Topotecan by convection-enhanced delivery has significant antitumor activity at concentrations that are nontoxic to normal brain. The potential for use of this therapy as a generally effective treatment option for malignant gliomas will be tested in subsequent phase II and III trials.


Drug Delivery Systems/methods , Glioma/drug therapy , Supratentorial Neoplasms/drug therapy , Topoisomerase I Inhibitors/administration & dosage , Topotecan/administration & dosage , Adult , Aged , Attention/drug effects , Convection , Drug Administration Schedule , Female , Follow-Up Studies , Glioma/diagnostic imaging , Glioma/pathology , Glioma/psychology , Humans , Magnetic Resonance Imaging , Male , Memory/drug effects , Middle Aged , Neurologic Examination , Neuropsychological Tests , Prospective Studies , Quality of Life , Reaction Time/drug effects , Supratentorial Neoplasms/diagnostic imaging , Supratentorial Neoplasms/pathology , Supratentorial Neoplasms/psychology , Surveys and Questionnaires , Tomography, X-Ray Computed , Young Adult
5.
Radiology ; 254(3): 698-706, 2010 Mar.
Article En | MEDLINE | ID: mdl-20177085

PURPOSE: To determine radiation doses from coronary computed tomographic (CT) angiography performed by using a 320-detector row volume scanner and evaluate how the effective dose depends on scan mode and the calculation method used. MATERIALS AND METHODS: Radiation doses from coronary CT angiography performed by using a volume scanner were determined by using metal-oxide-semiconductor field-effect transistor detectors positioned in an anthropomorphic phantom physically and radiographically simulating a male or female human. Organ and effective doses were determined for six scan modes, including both 64-row helical and 280-row volume scans. Effective doses were compared with estimates based on the method most commonly used in clinical literature: multiplying dose-length product (DLP) by a general conversion coefficient (0.017 or 0.014 mSv.mGy(-1).cm(-1)), determined from Monte Carlo simulations of chest CT by using single-section scanners and previous tissue-weighting factors. RESULTS: Effective dose was reduced by up to 91% with volume scanning relative to helical scanning, with similar image noise. Effective dose, determined by using International Commission on Radiological Protection publication 103 tissue-weighting factors, was 8.2 mSv, using volume scanning with exposure permitting a wide reconstruction window, 5.8 mSv with optimized exposure and 4.4 mSv for optimized 100-kVp scanning. Estimating effective dose with a chest conversion coefficient resulted in a dose as low as 1.8 mSv, substantially underestimating effective dose for both volume and helical coronary CT angiography. CONCLUSION: Volume scanning markedly decreases coronary CT angiography radiation doses compared with those at helical scanning. When conversion coefficients are used to estimate effective dose from DLP, they should be appropriate for the scanner and scan mode used and reflect current tissue-weighting factors. (c) RSNA, 2010.


Coronary Angiography , Radiation Dosage , Radiometry/methods , Tomography, X-Ray Computed , Body Burden , Female , Humans , Male , Monte Carlo Method , Phantoms, Imaging
6.
Neural Plast ; 2009: 768398, 2009.
Article En | MEDLINE | ID: mdl-20182547

This paper describes an individual who was diagnosed with obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) at age 17 when education was discontinued. By age 19, he was housebound without social contacts except for parents. Adequate trials of three selective serotonin reuptake inhibitors, two with atypical neuroleptics, were ineffective. Major exacerbations following ear infections involving Group A beta-hemolytic streptococcus at ages 19 and 20 led to intravenous immune globulin therapy, which was also ineffective. At age 22, another severe exacerbation followed antibiotic treatment for H. pylori. This led to a hypothesis that postulates deficient signal transduction by the N-methyl-D-aspartate receptor (NMDAR). Treatment with glycine, an NMDAR coagonist, over 5 years led to robust reduction of OCD/BDD signs and symptoms except for partial relapses during treatment cessation. Education and social life were resumed and evidence suggests improved cognition. Our findings motivate further study of glycine treatment of OCD and BDD.


Body Dysmorphic Disorders/drug therapy , Glycine/therapeutic use , Obsessive-Compulsive Disorder/drug therapy , Psychotropic Drugs/therapeutic use , Body Dysmorphic Disorders/diagnosis , Body Dysmorphic Disorders/metabolism , Glycine/administration & dosage , Glycine Agents/administration & dosage , Glycine Agents/therapeutic use , Humans , Male , Models, Neurological , Obsessive-Compulsive Disorder/diagnosis , Obsessive-Compulsive Disorder/metabolism , Psychotropic Drugs/administration & dosage , Receptors, N-Methyl-D-Aspartate/metabolism , Signal Transduction , Time Factors , Treatment Outcome , Young Adult
7.
Radiology ; 248(3): 807-16, 2008 Sep.
Article En | MEDLINE | ID: mdl-18710976

PURPOSE: To determine the incidence and associated risk factors of nephrogenic systemic fibrosis (NSF) in patients who undergo gadolinium-based contrast agent (GBCA)-enhanced magnetic resonance (MR) imaging. MATERIALS AND METHODS: Institutional review board approval was obtained for retrospective review of the medical records from two hospitals to identify all cases of biopsy-confirmed NSF and all patients administered a GBCA from January 1, 1997, to June 30, 2007. Informed patient consent was not required. The incidence of NSF was calculated for patients who received a standard dose of GBCA, patients who received a high dose, and subgroups of patients with renal impairment. RESULTS: Fifteen patients developed NSF after gadolinium-enhanced MR imaging. All of them had an estimated glomerular filtration rate (eGFR) lower than 30 mL/min, and 11 had acute renal failure or acute deterioration of chronic renal failure. The incidence of NSF after gadolinium-enhanced MR imaging without screening for renal function was zero of 74,124 patients with the standard dose of GBCA and 15 (0.17%) of 8997 patients with the high dose (P < .001). The NSF incidence associated with a high dose of GBCA increased to 0.4% in patients in a chronic hemodialysis program and to 8.8% in those who had an eGFR lower than 15 mL/min but were not undergoing hemodialysis (P < .001). The NSF incidence in the patients with acute renal failure who received a high dose when their creatinine level was increasing was 19% (11 of 58 patients) when hemodialysis was delayed for longer than 2 days. More patients with NSF had proinflammatory events, and compared with patients without NSF, these patients had lower pH, younger age, lower eGFR, elevated serum phosphorus levels, and a longer delay between GBCA injection and hemodialysis. CONCLUSION: For patients with an eGFR lower than 15 mL/min, hemodialysis helped to prevent NSF. For patients with an eGFR lower than 30 mL/min who received a high dose of GBCA, acute renal failure, delayed hemodialysis after contrast agent injection, proinflammatory events, and hyperphosphatemia were associated with increased risk of NSF.


Chelating Agents , Gadolinium , Magnetic Resonance Imaging/statistics & numerical data , Renal Insufficiency/epidemiology , Risk Assessment/methods , Scleroderma, Systemic/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Comorbidity , Humans , Incidence , Middle Aged , New York/epidemiology , Retrospective Studies , Risk Factors , Syndrome
9.
J Neurooncol ; 76(2): 185-91, 2006 Jan.
Article En | MEDLINE | ID: mdl-16151595

This study evaluated the role of proton magnetic resonance spectroscopic imaging (1H MRSI) in assessing the response of low-grade brain tumors to a chemotherapy-only treatment regimen. Specifically, it was of interest to assess if 1H MRSI could detect early tumor response to therapy prior to magnetic resonance imaging (MRI) changes, and to establish which spectral markers were sensitive to regional changes within and around a heterogeneous tumor mass. A total of 14 patients with lower-grade gliomas were evaluated by multislice 1H MRSI, MRI and clinical examination. Changes associated with chemotherapy were assessed by longitudinal comparisons of regional levels of choline (Cho), N-acetyl-L-aspartate (NAA), and lactate (Lac) relative to total creatine. These changes were, in turn, compared to changes on pre- and post-contrast MR images and to each patient's clinical status. In enhancing tumor regions, there was a significant association between an increase in Lac/Cr during treatment and decreased progression-free survival time. At baseline, a low NAA/Cr in normal-appearing brain tissue adjacent to non-enhancing tumor was associated with decreased progression-free survival time, as was an increase in Cho/Cr during chemotherapy. An increase in Cho/Cr and Lac/Cr in normal-appearing brain regions next to non-enhancing tumor in one patient was noted 2 months before MRI showed progressive disease. These results suggest that 1H MRSI can be a powerful adjunct to MRI in the assessment of tumor response to chemotherapy, and that Cho/Cr and Lac/Cr appear to be the most reliable markers of tumor progression and may predict response prior to MRI changes.


Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/pathology , Glioma/drug therapy , Glioma/pathology , Adult , Aspartic Acid/analogs & derivatives , Aspartic Acid/metabolism , Brain Neoplasms/metabolism , Choline/metabolism , Creatine/metabolism , Disease-Free Survival , Female , Glioma/metabolism , Humans , Lactic Acid/metabolism , Magnetic Resonance Imaging , Male , Middle Aged , Retrospective Studies , Treatment Outcome
10.
Radiology ; 234(2): 558-62, 2005 Feb.
Article En | MEDLINE | ID: mdl-15591432

All examinations were performed with approval from the institutional animal care and use committee of Columbia University. To assess the feasibility of real-time magnetic resonance (MR) imaging-guided neurovascular intervention in a swine model, the authors placed stents in the carotid arteries of five domestic pigs. Seven-French vascular sheaths were placed in the target carotid arteries via femoral access by using active MR tracking. Ten nitinol stents (8-10 x 20-40 mm) were successfully deployed in the target segments of carotid arteries bilaterally. MR imaging and necropsy findings confirmed stent position. Necropsy revealed no gross vascular injury. Study results demonstrated the feasibility of performing real-time MR imaging-guided neurovascular intervention by using an active-tracking technique in an animal model.


Carotid Arteries , Magnetic Resonance Angiography/instrumentation , Stents , Animals , Computer Systems , Feasibility Studies , Female , Magnetic Resonance Angiography/methods , Swine
11.
Radiology ; 234(2): 551-7, 2005 Feb.
Article En | MEDLINE | ID: mdl-15591433

All procedures and protocols were approved by the institutional animal care and use committee of Columbia University. To determine whether transfemoral catheterization of the carotid arteries can be performed entirely with real-time magnetic resonance (MR) imaging guidance, the authors catheterized the carotid arteries in six domestic pigs by using active-tracking catheters and guidewires and MR tracking software created for neurovascular procedures. The carotid arteries were successfully catheterized 24 times, on average within 5 minutes after insertion of the catheter into the femoral artery. Results demonstrated the feasibility of performing transfemoral catheterization of the carotid arteries with active MR tracking devices in a conventional MR imaging unit.


Carotid Arteries , Catheterization/methods , Magnetic Resonance Angiography/instrumentation , Animals , Feasibility Studies , Female , Femoral Artery , Magnetic Resonance Angiography/methods , Swine
12.
Surg Technol Int ; 11: 183-96, 2003.
Article En | MEDLINE | ID: mdl-12931300

Over the last two decades, interventional neuroradiologists have developed powerful techniques for the treatment of cerebrovascular disorders and brain tumors. Current interventional neuroradiological procedures are performed under X-ray fluoroscopy, which has allowed for high temporal and spatial resolution. However, these imaging techniques do not provide the treating physician with vital anatomic and functional information regarding vessel walls and the surrounding brain tissue. Better visualization of vessel structures and real-time information about the state of perfusion and metabolism of the surrounding brain tissue (real-time magnetic resonance arteriography, diffusion and perfusion-weighted imaging, apparent diffusion coefficient maps) would enhance safety and efficacy of neuroendovascular procedures available currently. Recent advances in magnetic resonance hardware and software have permitted significant enhancements in temporal and spatial resolution, which have resulted in the capability of visualizing anatomic structures with real-time fluoroscopy and angiography. This review outlines how real-time magnetic resonance procedures may replace conventional X-ray fluoroscopy in diagnostic and interventional neuroradiology during the next decade.


Brain Neoplasms/diagnosis , Cerebrovascular Disorders/diagnosis , Magnetic Resonance Angiography/methods , Radiographic Image Enhancement , Radiology, Interventional , Brain Neoplasms/surgery , Cerebrovascular Disorders/surgery , Contrast Media , Female , Humans , Magnetic Resonance Imaging/methods , Male , Sensitivity and Specificity , Severity of Illness Index , Tomography, X-Ray Computed , Ultrasonography, Doppler
...